PureTech Health (NASDAQ:PRTC) Trading Up 2% – Should You Buy?

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC)’s share price was up 2% on Wednesday . The company traded as high as $17.84 and last traded at $17.42. Approximately 7,177 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 18,326 shares. The stock had previously closed at $17.08.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut PureTech Health from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, PureTech Health has a consensus rating of “Sell”.

PureTech Health Stock Performance

The stock has a 50-day simple moving average of $16.85 and a 200 day simple moving average of $17.20.

PureTech Health (NASDAQ:PRTC) last released its quarterly earnings data on Friday, April 10th. The company reported ($1.35) EPS for the quarter. The company had revenue of $1.40 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP raised its position in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 as of its most recent SEC filing. 0.04% of the stock is owned by institutional investors and hedge funds.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.